A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis

A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease with few effective therapeutic options. Recently, drug repositioning, which involves identifying novel therapeutic potentials for existing drugs, has been popularized as a new approach for the development of nov...

Full description

Bibliographic Details
Main Authors: Takeshi Imakura, Seidai Sato, Kazuya Koyama, Hirohisa Ogawa, Takahiro Niimura, Kojin Murakami, Yuya Yamashita, Keiko Haji, Nobuhito Naito, Kozo Kagawa, Hiroshi Kawano, Yoshito Zamami, Keisuke Ishizawa, Yasuhiko Nishioka
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Respiratory Research
Subjects:
Polo-like kinase
Pulmonary fibrosis
In silico screening
Online Access:https://doi.org/10.1186/s12931-023-02446-x

Internet

https://doi.org/10.1186/s12931-023-02446-x

Similar Items